Contact
If you need media that scales, we'd like to help. Get in touch with us using the form below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
If you need media that scales, we'd like to help. Get in touch with us using the form below.
• Enhanced Post-Suspension Attachment: Proliferum B enables Wildtype’s salmon cell attachment post-suspension with performance exceeding FBS, addressing the bioreactor-to-scaffold transition bottleneck.
• Improved Morphology and Viability: Microscopy confirms Proliferum B promotes cellular spreading instead of unwanted clustered aggregates, while increasing survival by preventing apoptosis on scaffolds.
• Production-Ready ACF Solution: Proliferum B provides a scalable animal-component free pathway for structured cultivated seafood with regulatory advantages over FBS.
Wildtype, a pioneering cultivated seafood company based in San Francisco, began operations in 2016. With approximately 100 employees and over $125 million in funding, they await FDA approval for their first two seafood products, both of which have earned positive feedback in consumer taste tests.
The cultivated meat industry faces a critical technical hurdle: cells grown in suspension bioreactors struggle to properly attach to scaffolds when creating structured products. Wildtype observed these cells forming clustered aggregates rather than integrating with scaffolds. These poorly attached cells lack "biosynthetic power" -they don't stretch or deposit extracellular matrix proteins that enhance sensory attributes. While FBS overcomes this challenge, it fails on ethics, cost, scalability, and regulatory grounds - necessitating an animal-component-free (ACF) alternative.
Wildtype tested Proliferum B to find an ACF solution for post-suspension attachment that could match or exceed FBS performance. Their evaluation encompassed multiple experiments comparing Proliferum B formulations against controls in non-treated plates and proprietary scaffolds. Salmon cells from suspension culture were seeded at 50,000-100,000 cells/well and assessed at multiple timepoints through 7 days using microscopy to evaluate attachment quality, morphology, and viability through phase contrast and fluorescent imaging.
Proliferum B (10X) is a panel of four ACF formulations, allowing companies to determine which works best for their specific conditions. Multus developed these ready-to-use solutions using their AI-driven platform for optimal cell attachment in traditional and demanding environments.
Wildtype observed that Proliferum B transforms cell behaviour compared to other media.
"After testing many solutions, Proliferum B stands out as the only commercial product that matches FBS performance for post-suspension attachment. It has transformed our approach to scaffold integration without compromising our commitment to animal component-free production."
— Gaston Otarola Pezzani, Scientist at Wildtype
Key performance highlights include:
• Superior Cell Spreading: Microscopy showed Proliferum B induced spread morphologies versus rounded aggregate phenotypes in controls, exceeding FBS across all formulations and enabling uniform distribution rather than clustering.
• Enhanced Viability: After 7 days, Proliferum B maintained attachment with higher survival versus controls where cells detached and underwent apoptosis.
• Scaffold Integration: Confocal imaging revealed homogeneous distribution throughout scaffolds with significantly higher viability after two weeks.
• Consistent Performance: All four Proliferum B formulations (PB01-04) demonstrated comparable effectiveness.
Wildtype is evaluating how Proliferum B affects their products' mechanical properties long-term and has identified it as their leading commercial option. Multus is developing formulations that remove all human-derived sequences to ensure regulatory approval and price parity for production scale.
By enabling robust post-suspension cell attachment, Proliferum B offers larger-scale cultivated meat companies a clear pathway from high-volume bioreactor production to structured final products.
Technical Note: The effective transition from suspension to attachment culture involves reactivation of integrin pathways and cytoskeletal reorganisation. Proliferum B's unique formulation supports this process without animal-derived components.
Sign up for email updates:
